公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2005 | Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: Tissue accumulation and the reversibility after washout are tissue-selective | CHUN-JUNG LIN ; MEI-HWAN WU ; Hsueh Y.-M.; Sun S.S.-M.; ANN-LII CHENG | Cancer Chemotherapy and Pharmacology | 23 | 18 | |
2023 | Topoisomerase I Inhibition Radiosensitizing Hepatocellular Carcinoma by RNF144A-mediated DNA-PKcs Ubiquitination and Natural Killer Cell Cytotoxicity | CHIAO-LING TSAI ; Yang, Po-Sheng; FENG-MING HSU ; ANN-LII CHENG ; Yu, Wan-Ni; CHIA-HSIEN CHENG | Journal of clinical and translational hepatology | 2 | 1 | |
2015 | TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays | CHING-HUNG LIN ; Chen I.-C.; CHIUN-SHENG HUANG ; Hu F.-C.; WEN-HUNG KUO ; KUAN-TING KUO ; Wang C.-C.; Wu P.-F.; DWANG-YING CHANG ; Wang M.-Y.; Chang C.-H.; WEI-WU CHEN ; YEN-SHEN LU ; ANN-LII CHENG | Scientific Reports | 10 | 11 | |
1998 | Transactivation of the human MDR1 gene by hepatitis B virus X gene product | SHIN-LIAN DOONG ; Lin M.-H.; Tsai M.-M.; Li T.-R.; Chuang S.-E.; ANN-LII CHENG | Journal of Hepatology | 12 | 11 | |
2023 | Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma | HUANG-CHUN LIEN ; Hsu, Chia-Lang; YEN-SHEN LU ; WEI-WU CHEN ; I-CHUN CHEN ; Li, Yu-Chia; CHIUN-SHENG HUANG ; ANN-LII CHENG ; CHING-HUNG LIN | Breast cancer research : BCR | 0 | 0 | |
1997 | Transforming growth factor β1 attenuates ceramide-induced CPP32/Yama activation and apoptosis in human leukaemic HL-60 cells | Kuo M.-L.; Chen C.-W.; SHIOU-HWA JEE ; Chuang S.-E.; ANN-LII CHENG | Biochemical Journal | 18 | 19 | |
2010 | Translocation of Helicobacter pylori CagA into human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphoma | Lin W.-C.; Tsai H.-F.; SUNG-HSIN KUO ; MING-SHIANG WU ; CHUNG-WU LIN ; Hsu P.-I.; ANN-LII CHENG ; PING-NING HSU | Cancer Research | 79 | 69 | |
2015 | Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials | YU-YUN SHAO ; Shau, W.-Y.; Chan, S.-Y.; LI-CHUN LU ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology (Switzerland) | 29 | 29 | |
2000 | Treatment of recurrent Kaposi's sarcoma of an AIDS patient with weekly paclitaxel | CHIH-HUNG HSU ; Chen M.-Y.; ANN-LII CHENG | Anticancer Research | 6 | 4 | |
2017 | Treatment outcomes of and prognostic factors for definitive radiotherapy with and without chemotherapy for Stage I/II nasal extranodal NK/T-cell lymphoma | WEN-CHI YANG ; CHUN-WEI WANG ; RUEY-LONG HONG ; CHIAO-LING TSAI ; MING YAO ; JIH-LUH TANG ; CHUNG-WU LIN ; ANN-LII CHENG ; SUNG-HSIN KUO | Journal of Radiation Research | 9 | 9 | |
2017 | Tumor compactness improves the preoperative volumetrybased prediction of the pathological complete response of rectal cancer after preoperative concurrent chemoradiotherapy | CHE-YU HSU ; CHUN-WEI WANG ; Kuo C.-C.; YU-HSUAN CHEN ; KENG-HSUEH LAN ; ANN-LII CHENG ; SUNG-HSIN KUO | Oncotarget | 12 | 12 | |
2016 | Tumor heterogeneity in hepatocellular carcinoma: Facing the challenges | LI-CHUN LU ; CHIH-HUNG HSU ; CHIUN HSU ; ANN-LII CHENG | Liver Cancer | 95 | 98 | |
2020 | Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours | de Bono J.; CHIA-CHI LIN ; Chen L.-T.; Corral J.; Michalarea V.; Rihawi K.; Ong M.; JIH-HSIANG LEE ; CHIH-HUNG HSU ; CHIH-HSIN YANG ; Shiah H.-S.; Yen C.-J.; Anthoney A.; Jove M.; Buschke S.; Fuertig R.; Schmid U.; Goeldner R.-G.; Strelkowa N.; Huang D.C.-L.; Bogenrieder T.; Twelves C.; ANN-LII CHENG | British Journal of Cancer | 19 | 17 | |
2014 | Type 2 diabetes mellitus is associated with increased mortality in chinese patients receiving curative surgery for colon cancer | KUO-HSING CHEN ; YU-YUN SHAO ; ZHONG-ZHE LIN ; Yeh Y.-C.; Wen-Yi S.; Kuo R.N.; Chen H.-M.; Lai C.-L.; KUN-HUEI YEH ; ANN-LII CHENG ; Lai M.-S. | Oncologist | 24 | 19 | |
2021 | An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma | YU-YUN SHAO ; ANN-LII CHENG ; CHIH-HUNG HSU | Oncologist | 7 | 5 | |
2010 | Unusual presentation of multiple pathologic bone fractures in a patient with gastric mucosa-associated lymphoid tissue lymphoma | SUNG-HSIN KUO ; RUOH-FANG YEN ; CHUNG-WU LIN ; Chen L.-T.; HWEI-FANG TIEN ; ANN-LII CHENG | Annals of Hematology | 1 | 1 | |
2022 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma | ANN-LII CHENG ; Qin, Shukui; Ikeda, Masafumi; Galle, Peter R; Ducreux, Michel; Kim, Tae-You; Lim, Ho Yeong; Kudo, Masatoshi; Breder, Valeriy; Merle, Philippe; Kaseb, Ahmed O; Li, Daneng; Verret, Wendy; Ma, Ning; Nicholas, Alan; Wang, Yifan; Li, Lindong; Zhu, Andrew X; Finn, Richard S | Journal of hepatology | 490 | 463 | |
2022 | Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib | Kudo, Masatoshi; Finn, Richard S; Edeline, Julien; Cattan, Stéphane; Ogasawara, Sadahisa; Palmer, Daniel H; Verslype, Chris; Zagonel, Vittorina; Fartoux, Laetitia; Vogel, Arndt; Sarker, Debashis; Verset, Gontran; Chan, Stephen L; Knox, Jennifer; Daniele, Bruno; Yau, Thomas; Gurary, Ellen B; Siegel, Abby B; Wang, Anran; ANN-LII CHENG ; Zhu, Andrew X | European journal of cancer (Oxford, England : 1990) | 38 | 35 | |
2017 | Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer | Okusaka T.; Miyakawa H.; Fujii H.; Nakamori S.; Satoh T.; Hamamoto Y.; Ito T.; Maguchi H.; Matsumoto S.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; Chen J.S.; ANN-LII CHENG ; Sato A.; Ohashi Y.; Tanaka M.; on behalf of the GEST group | Journal of Cancer Research and Clinical Oncology | 25 | 18 | |
2019 | Urine protein:creatinine ratio vs 24-hour urine protein for proteinuria management: analysis from the phase 3 REFLECT study of lenvatinib vs sorafenib in hepatocellular carcinoma | Evans T.R.J.; Kudo M.; Finn R.S.; Han K.-H.; ANN-LII CHENG ; Ikeda M.; Kraljevic S.; Ren M.; Dutcus C.E.; Piscaglia F.; Sung M.W. | British Journal of Cancer | 19 | 19 | |